Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus

Berrin Ergun-Longmire, Karen Lin-Su, Ann M. Dunn, Lily Chan, Kirsis Ham, Cristina Sison, Joseph Stavola, Maria G. Vogiatzi

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the effects of protease inhibitors (PIs) as antiretroviral therapy in comparison with other antiretroviral (non-PI) medications on glucose tolerance, lipid metabolism, and body fat distribution in human immunodeficiency virus (HIV)-infected young patients. Methods: We conducted a cross-sectional clinical study in an outpatient HIV clinic. The study population consisted of 21 patients (15 female and 6 male) who had had at least 6 months of antiretroviral treatment. The mean age of the patients was 11.9 years (range, 6 to 16.5). Results: Fifteen patients treated with PIs and 6 patients treated with non-PIs were enrolled in the study. We found no significant differences in the lipid panel and insulin resistance, as determined by using the Quantitative Insulin Sensitivity Check Index formula, in the PI group in comparison with the non-PI group. Lipodystrophy was observed in 47% (7 of 15) of the PI group and 33% (2 of 6) of the non-PI group (P = 0.66). In the presence of lipodystrophy, serum triglyceride levels were higher in the PI group than in the non-PI group (P = 0.046). No such difference was found between the treatment groups when no lipodystrophy was present. There was no significant difference in insulin resistance between the treatment groups in the presence or absence of lipodystrophy. Conclusion: Our study found the presence of lipodystrophy in HIV-infected young patients regardless of whether they were taking PIs or not. In the patients who had lipodystrophy, those treated with PIs had higher serum triglyceride levels than those not treated with PIs.

Original languageEnglish (US)
Pages (from-to)514-521
Number of pages8
JournalEndocrine Practice
Volume12
Issue number5
StatePublished - Sep 2006

Fingerprint

Lipodystrophy
Body Composition
Protease Inhibitors
Lipid Metabolism
HIV
Glucose
Insulin Resistance
Serpin E2
Triglycerides
Body Fat Distribution
Therapeutics
Lipid Droplets
Serum
Outpatients
Cross-Sectional Studies
Lipids
Population

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. / Ergun-Longmire, Berrin; Lin-Su, Karen; Dunn, Ann M.; Chan, Lily; Ham, Kirsis; Sison, Cristina; Stavola, Joseph; Vogiatzi, Maria G.

In: Endocrine Practice, Vol. 12, No. 5, 09.2006, p. 514-521.

Research output: Contribution to journalArticle

Ergun-Longmire, Berrin ; Lin-Su, Karen ; Dunn, Ann M. ; Chan, Lily ; Ham, Kirsis ; Sison, Cristina ; Stavola, Joseph ; Vogiatzi, Maria G. / Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. In: Endocrine Practice. 2006 ; Vol. 12, No. 5. pp. 514-521.
@article{100bfa8dbbcc4ed7ae5abc4af7b71bd1,
title = "Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus",
abstract = "Objective: To evaluate the effects of protease inhibitors (PIs) as antiretroviral therapy in comparison with other antiretroviral (non-PI) medications on glucose tolerance, lipid metabolism, and body fat distribution in human immunodeficiency virus (HIV)-infected young patients. Methods: We conducted a cross-sectional clinical study in an outpatient HIV clinic. The study population consisted of 21 patients (15 female and 6 male) who had had at least 6 months of antiretroviral treatment. The mean age of the patients was 11.9 years (range, 6 to 16.5). Results: Fifteen patients treated with PIs and 6 patients treated with non-PIs were enrolled in the study. We found no significant differences in the lipid panel and insulin resistance, as determined by using the Quantitative Insulin Sensitivity Check Index formula, in the PI group in comparison with the non-PI group. Lipodystrophy was observed in 47{\%} (7 of 15) of the PI group and 33{\%} (2 of 6) of the non-PI group (P = 0.66). In the presence of lipodystrophy, serum triglyceride levels were higher in the PI group than in the non-PI group (P = 0.046). No such difference was found between the treatment groups when no lipodystrophy was present. There was no significant difference in insulin resistance between the treatment groups in the presence or absence of lipodystrophy. Conclusion: Our study found the presence of lipodystrophy in HIV-infected young patients regardless of whether they were taking PIs or not. In the patients who had lipodystrophy, those treated with PIs had higher serum triglyceride levels than those not treated with PIs.",
author = "Berrin Ergun-Longmire and Karen Lin-Su and Dunn, {Ann M.} and Lily Chan and Kirsis Ham and Cristina Sison and Joseph Stavola and Vogiatzi, {Maria G.}",
year = "2006",
month = "9",
language = "English (US)",
volume = "12",
pages = "514--521",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "5",

}

TY - JOUR

T1 - Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus

AU - Ergun-Longmire, Berrin

AU - Lin-Su, Karen

AU - Dunn, Ann M.

AU - Chan, Lily

AU - Ham, Kirsis

AU - Sison, Cristina

AU - Stavola, Joseph

AU - Vogiatzi, Maria G.

PY - 2006/9

Y1 - 2006/9

N2 - Objective: To evaluate the effects of protease inhibitors (PIs) as antiretroviral therapy in comparison with other antiretroviral (non-PI) medications on glucose tolerance, lipid metabolism, and body fat distribution in human immunodeficiency virus (HIV)-infected young patients. Methods: We conducted a cross-sectional clinical study in an outpatient HIV clinic. The study population consisted of 21 patients (15 female and 6 male) who had had at least 6 months of antiretroviral treatment. The mean age of the patients was 11.9 years (range, 6 to 16.5). Results: Fifteen patients treated with PIs and 6 patients treated with non-PIs were enrolled in the study. We found no significant differences in the lipid panel and insulin resistance, as determined by using the Quantitative Insulin Sensitivity Check Index formula, in the PI group in comparison with the non-PI group. Lipodystrophy was observed in 47% (7 of 15) of the PI group and 33% (2 of 6) of the non-PI group (P = 0.66). In the presence of lipodystrophy, serum triglyceride levels were higher in the PI group than in the non-PI group (P = 0.046). No such difference was found between the treatment groups when no lipodystrophy was present. There was no significant difference in insulin resistance between the treatment groups in the presence or absence of lipodystrophy. Conclusion: Our study found the presence of lipodystrophy in HIV-infected young patients regardless of whether they were taking PIs or not. In the patients who had lipodystrophy, those treated with PIs had higher serum triglyceride levels than those not treated with PIs.

AB - Objective: To evaluate the effects of protease inhibitors (PIs) as antiretroviral therapy in comparison with other antiretroviral (non-PI) medications on glucose tolerance, lipid metabolism, and body fat distribution in human immunodeficiency virus (HIV)-infected young patients. Methods: We conducted a cross-sectional clinical study in an outpatient HIV clinic. The study population consisted of 21 patients (15 female and 6 male) who had had at least 6 months of antiretroviral treatment. The mean age of the patients was 11.9 years (range, 6 to 16.5). Results: Fifteen patients treated with PIs and 6 patients treated with non-PIs were enrolled in the study. We found no significant differences in the lipid panel and insulin resistance, as determined by using the Quantitative Insulin Sensitivity Check Index formula, in the PI group in comparison with the non-PI group. Lipodystrophy was observed in 47% (7 of 15) of the PI group and 33% (2 of 6) of the non-PI group (P = 0.66). In the presence of lipodystrophy, serum triglyceride levels were higher in the PI group than in the non-PI group (P = 0.046). No such difference was found between the treatment groups when no lipodystrophy was present. There was no significant difference in insulin resistance between the treatment groups in the presence or absence of lipodystrophy. Conclusion: Our study found the presence of lipodystrophy in HIV-infected young patients regardless of whether they were taking PIs or not. In the patients who had lipodystrophy, those treated with PIs had higher serum triglyceride levels than those not treated with PIs.

UR - http://www.scopus.com/inward/record.url?scp=33947359492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947359492&partnerID=8YFLogxK

M3 - Article

C2 - 17014060

AN - SCOPUS:33947359492

VL - 12

SP - 514

EP - 521

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 5

ER -